Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling
Open Access
- 9 October 2021
- journal article
- research article
- Published by Elsevier BV in Online Journal of Public Health Informatics
- Vol. 297 (5), 101291
- https://doi.org/10.1016/j.jbc.2021.101291
Abstract
No abstract availableFunding Information
- Cancer Research Society (24071)
- Canadian Institutes of Health Research (GER-163050, MOP-133442)
- Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-05227)
- Fonds de Recherche du Québec - Santé
- Fonds de Recherche du Québec Nature et Technologies (2019-PR-254641)
This publication has 62 references indexed in Scilit:
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTORMolecular Cell, 2011
- mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTORMolecular Cell, 2011
- DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and AutophagyMolecular Cell, 2011
- Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cellsCellular Signalling, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survivalJournal of Neuro-Oncology, 2009
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009